News
The day at a glance · 3 min read
Mood · Risk-On
+68
Sentiment, −100 to +100
AbbVie Q3 Revenue
$17.4b
AbbVie Q3 EPS
$2.38
AbbVie Stock Move
$294.83+3.1%
Key driverStrong Q3 earnings from AbbVie and UnitedHealth, coupled with WHO backing for Moderna's Ebola vaccine candidate, drove healthcare sector gains
Daily briefHealthcare· Money365.Market AI ·

AbbVie, UnitedHealth Q3 Beats; Moderna WHO Nod Fuels Rally

Big Pharma earnings impress while Vir and Adaptive post diagnostics progress; Eli Lilly secures advertising win on compounded weight-loss drugs

Big Pharma Earnings & Pipeline

Bullish

T-Therapeutics Series B

$133M
01ABBV
AbbVie (ABBV) reported Q3 2026 net revenue of $17.4b and basic earnings per share of $2.38, raising full-year adjusted earnings guidance and driving a 3.1% share price gain to approximately $294.83 following the release. The stock had already climbed 21% over the prior three months ahead of the Q3 report.
02LLY
Eli Lilly (LLY) has secured changes to a competitor's advertising for compounded Tirzepatide products after raising concerns about product integrity and patient protection, intensifying legal and regulatory pressure on providers of compounded weight-loss drugs. Management is reshaping the company's research pipeline through acquisitions, program divestments, and discontinuations that tilt investment toward select therapeutic areas.
03LLY
T-Therapeutics closed an oversubscribed $133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional investments from Johnson & Johnson Innovation – JJDC (JNJ), Samsara BioCapital, M-Ventures and Lilly (LLY), joined by all existing major shareholders. Proceeds will fund two first-in-class TCR-CD3 bispecific programs in cancer and autoimmune disease through to clinical proof-of-concept.

Biotech & Vaccines

Bullish

Moderna 1-Day Return

13.1%+13.1%

Moderna 7-Day Return

20.7%+20.7%

Vir-Gilead Collaboration

$90M
01MRNA▲ +13.11%
Moderna (MRNA) drew focus after the World Health Organization's technical advisory group backed its Bundibugyo ebolavirus vaccine candidate, mRNA-1469, to progress into a Phase 2/3 efficacy study in the Democratic Republic of the Congo. The mRNA-1469 update landed on a stock already on a steep upswing, with a 1-day share price return of 13.1%, a 7-day gain of 20.7%, and a 90-day move of almost 4x.
02VIR
Vir Biotechnology (VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, according to executives on the company's third-quarter earnings call. The company eyes pivotal ECLIPSE 1 hepatitis Delta results this quarter while a $90 million Gilead (GILD) collaboration and FDA Fast Track designation for VIR-5500 reinforce its late-stage pipeline.

Diagnostics & MedTech

Bullish

Adaptive Q3 Revenue

$83.9M

Adaptive Adj. EBITDA

$14.3M
01ADPT
Adaptive Biotechnologies (ADPT) posted $83.9 million in quarterly revenue, swung to positive adjusted EBITDA of $14.3 million, and raised full-year MRD guidance on strong ClonoSeq volume growth, marking its first profitable quarter. The diagnostics company delivered a significant operational milestone in its Q3 2026 earnings report.
02GH
Guardant Health (GH) reported that its Shield blood test for colorectal cancer screening received the 2026 Prix Galien USA Award for Best Medical Technology, recognizing the first FDA-approved blood test for primary colorectal cancer screening and its role in raising screening participation and adherence in real-world use. The company also added Kevin Sayer, former Dexcom (DXCM) CEO and current Executive Chairman, to its board, bringing deep digital health operating experience and governance insight.

Managed Care & Insurance

Bullish

UNH Q3 Adj. EPS

$4.69

UNH Q3 Revenue

$113B

UNH Stock Price

$409+1.2%
01UNH
UnitedHealth Group (UNH) released Q3 2026 results showing adjusted earnings per share of approximately $4.69 on revenue slightly above $113b, driving a measured 1.2% share price gain in regular trading to around $409. The main question for investors is whether this quarter signals a genuine easing in medical cost pressure or simply a brief pause in a longer period of margin compression.

Other Developments

Neutral

OPKO Q3 Revenue

$65.4M+16%

OPKO LabCorp Cash

$722M

XLV Net Purchases

$330.3M

DIA Stock Sales

$310.2M
01OPK
OPKO Health (OPK) posted $65.4 million in Q3 2026 revenue and a $722 million LabCorp cash windfall, while widening biotech losses and a delayed CAR-T timeline tempered the outlook. The company delivered 16% revenue growth despite operational challenges in its development programs.
02LLY
The State Street Health Care SPDR fund (XLV) added $330.3 million in net purchases, lifting all 60 of its positions with no sells, with Eli Lilly (LLY) leading the buys. The Spdr Dow Jones Industrial Average ETF (DIA), a $44.89 billion fund, sold $310.2 million of stock, trimming all 30 positions including Amgen (AMGN) and buying nothing.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy